These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

939 related articles for article (PubMed ID: 29467147)

  • 1. Alectinib for advanced
    Ly AC; Olin JL; Smith MB
    Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
    Tomasini P; Egea J; Souquet-Bressand M; Greillier L; Barlesi F
    Ther Adv Respir Dis; 2019; 13():1753466619831906. PubMed ID: 30786826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
    Paik J; Dhillon S
    Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alectinib shows CNS efficacy in ALK-positive NSCLC.
    Gourd E
    Lancet Oncol; 2018 Oct; 19(10):e520. PubMed ID: 30245054
    [No Abstract]   [Full Text] [Related]  

  • 10. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Morcos PN; Nueesch E; Jaminion F; Guerini E; Hsu JC; Bordogna W; Balas B; Mercier F
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):129-138. PubMed ID: 29748847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
    Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
    Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
    Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
    J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.